Avian influenza A (H5N1) infection in a patient in China, 2006

Chen, X.; Smith, Gavin J. D.; Zhou, Boping; Qiu, Chen; Wu, Wai Lan; Li, Y.; Lu, Pu-Xuan; Duan, Lian; Liu, S.; Yuan, Jing; Yang, Guang; Wang, H.; Cheng, Jinquan; Jiang, Hui; Peiris, Malik; Chen, H.; Yuen, Kwok‐Yung; Zhong, Nanshan; Guan, Yi

doi:10.1111/j.1750-2659.2007.00032.x

Cited by 7 publications

(4 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The virus subsequently spread among poultry in Hong Kong. Despite strict control measures, the virus spread to many countries worldwide, resulting in high mortality in poultry and fatal infections in mammalian species, including humans [122][123][124]. The first natural infection by the H5N1 subtype in domestic cats was described in Bangkok (Thailand) in February 2004 in a fatal outbreak in 15 household cats with vomiting and coughing up blood.…”

Section: Influenza Viruses In Catsmentioning

confidence: 99%

Emerging Respiratory Viruses of Cats

Palombieri

Profio

Fruci

et al. 2022

Viruses

View full text Add to dashboard Cite

In recent years, advances in diagnostics and deep sequencing technologies have led to the identification and characterization of novel viruses in cats as protoparviruses and chaphamaparvoviruses, unveiling the diversity of the feline virome in the respiratory tract. Observational, epidemiological and experimental data are necessary to demonstrate firmly if some viruses are able to cause disease, as this information may be confounded by virus- or host-related factors. Also, in recent years, researchers were able to monitor multiple examples of transmission to felids of viruses with high pathogenic potential, such as the influenza virus strains H5N1, H1N1, H7N2, H5N6 and H3N2, and in the late 2019, the human hypervirulent coronavirus SARS-CoV-2. These findings suggest that the study of viral infections always requires a multi-disciplinary approach inspired by the One Health vision. By reviewing the literature, we provide herewith an update on the emerging viruses identified in cats and their potential association with respiratory disease.

show abstract

Section: Influenza Viruses In Catsmentioning

confidence: 99%

Emerging Respiratory Viruses of Cats

Palombieri

Profio

Fruci

et al. 2022

Viruses

View full text Add to dashboard Cite

show abstract

“…The scientific community anticipates that a future influenza pandemic is likely to originate from animals; however, many scientists were surprised that the 2009 pandemic may have originated from swine (481) and not from avian populations, which had been severely affected by the H5N1 and H9N2 viruses since 1997, with occasional poultry-to-human transmission (25,52,103,104,214,215,439,440,576). In the prepandemic period, intensive screening was dedicated to poultry surveillance, especially in East Asia, where the lethal H5N1 first emerged (94,214,215,351,576) and where antigenically drifted H3N2 strains often emerged and spread throughout the world (462).…”

Section: Animal Surveillancementioning

confidence: 99%

Two Years after Pandemic Influenza A/2009/H1N1: What Have We Learned?

et al. 2012

View full text Add to dashboard Cite

SUMMARY The world had been anticipating another influenza pandemic since the last one in 1968. The pandemic influenza A H1N1 2009 virus (A/2009/H1N1) finally arrived, causing the first pandemic influenza of the new millennium, which has affected over 214 countries and caused over 18,449 deaths. Because of the persistent threat from the A/H5N1 virus since 1997 and the outbreak of the severe acute respiratory syndrome (SARS) coronavirus in 2003, medical and scientific communities have been more prepared in mindset and infrastructure. This preparedness has allowed for rapid and effective research on the epidemiological, clinical, pathological, immunological, virological, and other basic scientific aspects of the disease, with impacts on its control. A PubMed search using the keywords “pandemic influenza virus H1N1 2009” yielded over 2,500 publications, which markedly exceeded the number published on previous pandemics. Only representative works with relevance to clinical microbiology and infectious diseases are reviewed in this article. A significant increase in the understanding of this virus and the disease within such a short amount of time has allowed for the timely development of diagnostic tests, treatments, and preventive measures. These findings could prove useful for future randomized controlled clinical trials and the epidemiological control of future pandemics.

show abstract

“…Although well‐established models exist for use of fractionated products derived of convalescent plasma, such as pathogen‐specific HIG, 18,19,60 evidence of H1N1‐specific, H5N1‐specific, or other strain‐specific passive immunity for influenza is still limited largely to case reports of convalescent serotherapy (Table 2). 61‐64 Clinical trials of serotherapy for influenza are limited to historical reports, which have been recently examined in a unique meta‐analysis, which could prove useful in response to the current H1N1 pandemic 65 . Recent case reports of its use for H5N1‐infected patients are promising, but limited and uncontrolled.…”

Section: Convalescent Plasma Transfusions (Aka Serum Therapy)mentioning

confidence: 99%

Convalescent transfusion for pandemic influenza: preparing blood banks for a new plasma product?

2010

View full text Add to dashboard Cite

Due to the potential of a severe pandemic to limit efficacy or availability of medical countermeasures, some researchers have begun a search for new interventions that could complement the planned antiviral- and vaccine-based response to an influenza pandemic. One such countermeasure-the transfusion of pandemic influenza-specific antibodies from surviving patients to the clinically ill-is the focus of this commentary. Passive immunotherapy, which includes the use of monoclonal antibodies (MoAbs), hyperimmune globulin, or convalescent plasma, had been used before the advent of antibiotics and has recently reentered the limelight due to the accelerating development of MoAb therapies against cancer, a number of microbes, allograft rejection, and a host of other conditions. After the plausible biologic mechanism and somewhat limited data supporting the efficacy for this modality against influenza are reviewed, safety and logistical concerns for utilization of this potential new product (fresh convalescent plasma against influenza [FCP-Flu]) are discussed. FCP-Flu could indeed prove useful in a response to a pandemic, but two necessary items must first be satisfied. Most importantly, more research should be conducted to establish FCP-Flu efficacy against the current and other pandemic strains. Second, and also importantly, blood banks and donor centers should examine whether offering this new product would be feasible in a pandemic and begin planning before a more severe pandemic forces us to respond without adequate preparation.

show abstract

Avian influenza A (H5N1) infection in a patient in China, 2006

Cited by 7 publications

References 28 publications

Emerging Respiratory Viruses of Cats

Emerging Respiratory Viruses of Cats

Two Years after Pandemic Influenza A/2009/H1N1: What Have We Learned?

Convalescent transfusion for pandemic influenza: preparing blood banks for a new plasma product?

Contact Info

Product

Resources

About